Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 3/20 | 0.79 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.78 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.78 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.78 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 1/20 | 0.78 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.73 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.73 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440267 | 1.00 | RNASEL (0.79) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL27354672 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL27354649 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL27255598 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL1620285 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL1620290 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL27254840 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL30250157 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL27354758 | 0.99 | RNASEL (0.81) | RNASELP2RY1P2RY2P2RX1P2RX3 | |
| SCHEMBL7260957 | 0.96 | RNASEL (0.82) | RNASELP2RY1P2RY2P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3625363-A1 | METHOD FOR DETERMINING AT LEAST ONE QUALITY PARAMETER OF AN RNA SAMPLE | CureVac Real Estate GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| WO-2018211038-A1 | METHOD FOR DETERMINING AT LEAST ONE QUALITY PARAMETER OF AN RNA SAMPLE | CUREVAC AG (DE) | 2018-11-22 | — | — | WO | claimed |
| US-20120308987-A1 | MATRICES AND MEDIA FOR STORAGE AND STABILIZATION OF BIOMOLECULES | GENVAULT CORPORATION (US) | 2012-12-06 | — | — | US | claimed |
| US-8283165-B2 | Matrices and media for storage and stabilization of biomolecules | GENVAULT CORPORATION (US) | 2012-10-09 | — | — | US | claimed |
| US-20100248363-A1 | MATRICES AND MEDIA FOR STORAGE AND STABILIZATION OF BIOMOLECULES | GENVAULT CORPORATION (US) | 2010-09-30 | — | — | US | claimed |
| US-20250270634-A1 | METHOD FOR DETERMINING AT LEAST ONE QUALITY PARAMETER OF AN RNA SAMPLE | CureVac Manufacturing GmbH (DE) | 2025-08-28 | — | — | US | disclosed |
| WO-2025109302-A2 | IN VITRO TRANSCRIPTION METHOD | THE UNIVERSITY OF SHEFFIELD (GB) | 2025-05-30 | — | — | WO | disclosed |
| US-20250163502-A1 | METHODS FOR PROCESSING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12297489-B2 | Method for determining at least one quality parameter of an RNA sample | CureVac Manufacturing GmbH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-20240376521-A1 | BORONIC ACID COMPOSITIONS AND METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4461816-A1 | BORONIC ACID COMPOSITIONS AND METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X Genomics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240218424-A1 | METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0891373-A1 | METHOD AND COMPOUNDS FOR INHIBITION OF RIBONUCLEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5852001-A | Method and compounds for inhibition of ribonucleases | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998028321-A1 | METHOD AND COMPOUNDS FOR INHIBITION OF RIBONUCLEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0636022-A1 | CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS | OCULON CORPORATION (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1994026259-A1 | CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS | OCULON CORPORATION (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5338545-A | Administering Coenzyme A | OCULON CORPORATION (US) | 1994-08-16 | — | — | US | disclosed |
| WO-1993020805-A1 | CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS | OCULON CORPORATION (US) | 1993-10-28 | — | — | WO | disclosed |